913. Currently Used Adjuvants
Session: Symposium: Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses
Friday, October 5, 2018: 9:10 AM
Room: W 2014-2016
Nathalie Garcon, PharmD, PhD, BIOASTER, Lyon, France; BIOASTER, LYON, France

Nathalie Garçon is currently the chief executive (CEO) and scientific officer (CSO) of BIOASTER. She joined BIOASTER, the French technology research institute for infectiology and microbiology as chief scientific officer in July 2014. In this role, Dr Garçon directs the scientific aspect of the institute with the objective of accelerating the access to new technologies in infectious diseases that patient can benefit from. She was promoted to CEO in April 2015. Dr Garçon is a biological Pharmacist by training, and following the successful completion of two PhDs, one in pharmaceutical science and one in immunotoxicology / immunopharmacology, Dr Garçon moved to the UK for 1 year as a postdoctoral research fellow (the Royal Free Hospital London) undertaking research on liposomes in vaccines. After 4 years spend as postdoctoral research fellow, then as research assistant professor at Baylor College of Medicine in Houston, Texas, working on vaccine delivery systems and immunopotentiators, Dr Garçon joined SmithKline Beecham Biologicals now GlaxoSmithKline Vaccines in 1990, where she set up and led the vaccine adjuvant and formulation group. She moved from this position, to head of formulation technologies, head of research, vice president, head of global research and North America RD; and vice president, head of the global adjuvants and delivery systems centre for vaccines. In her last role within GSK vaccines before joining BIOASTER, Dr Garçon hold the position of vice president, head of adjuvants and technologies innovation center, where she provided leadership within GSK vaccines in the fields of new vaccines technologies, from discovery to registration and commercialization. Dr Garçon expertise in vaccinology extends from research to manufacturing, in particular immunology, adjuvant and formulation technologies, analytical methods, animal experimentation and toxicology/safety evaluation and testing. Dr Garçon is the 2014 laureate of the Stanley Plotkin award for lifetime achievement in the field of vaccines and vaccine technologies. She has authored over 70 papers and book chapters, and holds more than 100 patents.

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.